Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor

By sjmartinez • September 8, 2024

Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown JR, Barata P, Murgić J, Miletić M, Johnson J, Zakharia Y, Hui G, Drakaki A, Duran I, Buznego LA, Barrera RM, Castañeda DM, Rey-Cárdenas M, Castellano D, Nguyen CB, Park JJ, Alva A, McKay RR, Stewart TF, Epstein IB, Bellmunt J, Wright JL, Gupta S, Grivas P, Khaki AR. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clin Genitourin Cancer. 2024 Aug 12;22(6):102198. doi: 10.1016/j.clgc.2024.102198. Epub ahead of print. PMID: 39241315.

Tags: biomarkers, Bladder cancer, Fellow, Genomics, Hematology/Oncology, immunotherapy, Publications, urothelial carcinoma

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

Wainberg ZA, Link JM, Premji A, Zheng S, Srienc M, Hammons M, Kim SE, Li L, Liu Z, Tsvetkova O, Abt ER, Rosen L, Kim[...]

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

Kendra KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, Campbell KM, Carson WE 3rd, Wada DA, Plaza JA, In GK, Ikeguchi A, Hyngstrom J, Brohl AS,[...]

Detecting clinically relevant topological structures in multiplexed spatial proteomics using TopKAT

Samorodnitsky S, Campbell K, Little A, Ling W, Zhao N, Chen YC, Wu MC. Detecting clinically relevant topological structures in multiplexed spatial proteomics using TopKAT.[...]